For patients with acute lymphoblastic leukemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly ...
Jan 12, 2022
0
8
For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...
Mar 21, 2022
0
13
Researchers have developed a new protocol for monitoring acute lymphoblastic leukemia (ALL), the most common cancer in children, to inform more effective treatment strategies and detect disease recurrence. The personalized ...
Feb 8, 2022
0
6
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from ...
Feb 13, 2021
0
5
Analyzing sodium levels in breast cancer tumors can give an accurate indication of how aggressive a cancer is and whether chemotherapy treatments are taking effect, new research has shown.
Apr 25, 2022
0
540
Leukemia starts in cells that would normally develop into different types of blood cells. About 61,000 people in the U.S. are diagnosed each year, and depending on the type of leukemia and the age of the patient, five-year ...
Jun 8, 2022
0
27
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
Feb 25, 2021
0
24
Pancreatic cancer tumors are being missed on CT and MRI scans, narrowing the window for life-saving curative surgery, research presented today at UEG Week 2022 has revealed.
Oct 10, 2022
0
14
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative ...
Jun 28, 2018
0
67
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) ...
Sep 18, 2021
0
58
